Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality

To determine if a unique subtype of scleroderma muscle disease exists by comparing the clinical features of systemic sclerosis (SSc; scleroderma) patients with predominant fibrosis on muscle biopsy to those with inflammatory muscle histopathology.

[1]  L. Hummers,et al.  Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma , 2016, Arthritis care & research.

[2]  L. Hummers,et al.  Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire‐Disability Index (HAQ‐DI) in scleroderma , 2016 .

[3]  Ami A. Shah,et al.  Spectrum of Muscle Histopathologic Findings in Forty‐Two Scleroderma Patients With Weakness , 2015, Arthritis care & research.

[4]  P. Chinnery,et al.  Evaluation and Treatment of Myopathies , 2015, European Journal of Human Genetics.

[5]  W. Kaltenborn,et al.  The Single-Breath Carbon Monoxide Diffusing Capacity , 2015 .

[6]  M. Hudson,et al.  Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort , 2014, Scandinavian journal of rheumatology.

[7]  M. Baron,et al.  The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review , 2013, The Journal of Rheumatology.

[8]  S. Danoff,et al.  Anti–Melanoma Differentiation–Associated Protein 5–Associated Dermatomyositis: Expanding the Clinical Spectrum , 2013, Arthritis care & research.

[9]  T. Medsger,et al.  Anti-U3 RNP autoantibodies in systemic sclerosis. , 2009, Arthritis and rheumatism.

[10]  S. Eustace,et al.  Muscle Edema: Classification, Mechanisms, and Interpretation , 2006, Seminars in musculoskeletal radiology.

[11]  R. Hughes,et al.  119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[12]  A. Silman,et al.  A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.

[13]  W. Kaltenborn,et al.  The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. , 1987, The American review of respiratory disease.

[14]  J. Moossy,et al.  Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). , 1968, Arthritis and rheumatism.

[15]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[16]  T. Medsger,et al.  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. , 1993, American heart journal.

[17]  H. Paulus,et al.  Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. , 1978, Arthritis and rheumatism.